SCHEMBL6087977

SCHEMBL6087977

CCCC(=O)Nc1ccc2c(c1)/C(=C1/C(=O)Nc3ccccc31)OC2

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.54
MAPT P10636 4/20 0.54
NPC1 O15118 2/20 0.51
RAB9A P51151 2/20 0.51
ALDH1A1 P00352 4/20 0.50
HPGD P15428 2/20 0.50
PTPRC P08575 2/20 0.49
TLK2 Q86UE8 1/20 0.48
ALOX12 P18054 1/20 0.43
AAK1 Q2M2I8 1/20 0.43
LMNA P02545 2/20 0.42
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
PKM P14618 1/20 0.41
HTR1A P08908 2/20 0.41
RXFP1 Q9HBX9 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
AKT1 P31749 1/20 0.40
HTR7 P34969 1/20 0.40
CASP3 P42574 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6087979 1.00 KDM4E (0.54) KDM4EMAPTNPC1RAB9AALDH1A1
SCHEMBL6087897 0.89 CASP3 (0.49) KDM4EMAPTNPC1RAB9AALDH1A1
SCHEMBL6087901 0.89 CASP3 (0.49) KDM4EMAPTNPC1RAB9AALDH1A1
SCHEMBL6105082 0.87 ALDH1A1 (0.47) KDM4EMAPTNPC1RAB9AALDH1A1
SCHEMBL6105079 0.87 ALDH1A1 (0.47) KDM4EMAPTNPC1RAB9AALDH1A1
Cyclopropane SCHEMBL14715505 0.85 KDR (0.40) KDM4EMAPTALDH1A1TLK2LMNA
SCHEMBL6089198 0.83 MAOA (0.44) MAPTMEN1KMT2A
SCHEMBL6089195 0.83 MAOA (0.44) MAPTMEN1KMT2A
SCHEMBL6088404 0.83 ROCK2 (0.49) KDM4EMAPTRAB9AALDH1A1HPGD
SCHEMBL6088413 0.83 ROCK2 (0.49) KDM4EMAPTRAB9AALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490356-B1 (3Z)-3-(3-HYDRO-ISOBENZOFURAN-1-YLIDENE)-1,3-DIHYDRO-2H-INDOL-2-ONES AS KINASE INHIBITORS ALLERGAN INC (US) 2013-02-27 EP claimed
US-20040019098-A1 (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2004-01-29 US claimed
US-6541504-B1 Modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation. ALLERGAN SALES, LLC 2003-04-01 US claimed
EP-1490356-B1 (3Z)-3-(3-HYDRO-ISOBENZOFURAN-1-YLIDENE)-1,3-DIHYDRO-2H-INDOL-2-ONES AS KINASE INHIBITORS ALLERGAN INC (US) 2013-02-27 EP disclosed
US-7060844-B2 (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. (US) 2006-06-13 US disclosed
US-20060004084-A1 (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2006-01-05 US disclosed
US-6541504-B1 Modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation. ALLERGAN SALES, LLC 2003-04-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004084-A1 (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors CDK2, ERBB2, MAP3K3 KDM4E 1074/4885MAPT 2806/4885NPC1 3955/4885
US-20040019098-A1 (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors CDK2, ERBB2, MAP3K3 KDM4E 1176/4885MAPT 2710/4885NPC1 3871/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.